Opinion in Germany

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
Expert View
Expert View

Arcandor under threat of insolvency

While unconfirmed at present, it looks increasingly likely that Arcandor will not receive the necessary state guarantees for its outstanding debt. The company needs to raise E960m for 2009, with up to E900m to follow over the next five years. By June 12, when outstanding credit has to be renewed, Arcandor, the holding company of Karstadt, Thomas Cook and Quelle, could enter insolvency.

Published By Datamonitor
08 Jun 2009
CommentWire
CommentWire

Arcandor: sliding deeper into the red

Germany-based retail and travel company Arcandor saw its financial position deteriorate in the quarter to December 31, 2008 as costs accumulated due to restructuring work at Thomas Cook and its mail order arm saw losses of E58m (group EBIT). Although the sales performance of department store Karstadt has stabilized, Verdict Research is skeptical as to whether this signals a sustainable turnaround.

Published By Datamonitor
13 Feb 2009
ResearchWire
ResearchWire

Arthritis: sales will hit $24 billion in 2007

Published By Datamonitor
23 Apr 2001
CommentWire
CommentWire

Asset unbundling: utilities seek to prolong the status quo

Several German utilities have reportedly put forward proposals to merge their networks with those of foreign competitors as an alternative to divesting these operations. This shows that vertically integrated utilities are changing their recusant stance towards the European Commission's proposal of strict asset unbundling, in an effort to mitigate the proposals and preserve network ownership.

Published By Datamonitor
19 Mar 2007
ResearchWire
ResearchWire

Asthma: prevalence to increase worldwide

Published By Datamonitor
28 Jan 2002
ResearchWire
ResearchWire

Asthma: two-thirds of patients suffer persistently

Published By Datamonitor
15 Apr 2005
ResearchWire
ResearchWire

Asthma: UK top for diagnosis, US bottom

Published By Datamonitor
04 Feb 2002
CommentWire
CommentWire

AstraZeneca/Schwarz: contrasting ulcer fortunes

Company results released on 30 April by companies on either side of the branded versus generic fence show contrasting fortunes in the valuable market for ulcer drug omeprazole. While AstraZeneca's gastrointestinal franchise shrank by 3% compared with a year before, Schwarz's increased omeprazole manufacturing capacity is helping to drive growth.

Published By Datamonitor
02 May 2003
CommentWire
CommentWire

AstraZeneca/Targacept: another nail in the coffin for TC-5214

New top-line data show that the innovative nicotinic receptor antagonist TC-5214 has once again failed to demonstrate efficacy as an add-on to antidepressants in patients with major depressive disorder. Approval now seems highly unlikely, leaving Targacept without a lead candidate and AstraZeneca with a hefty loss.

Published By Datamonitor
20 Dec 2011
CommentWire
CommentWire

AstraZeneca: Crestor experiences additional setbacks

Withdrawal from the European approval process by three member states represents additional obstacles for Crestor, heightens concerns over safety, and will undoubtedly slow revenue gains for AstraZeneca. Therefore, although forecast to achieve blockbuster sales of $3.8 billion in 2010, Crestor will fail to make as significant an impact on the anti-dyslipidemic market as Lipitor did upon launch.

Published By Datamonitor
12 Mar 2003

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.